- Vienna 2018
- Athens 2019
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
First Author: N.Soeters THE NETHERLANDS
Co Author(s): S. Torregrosa N. Tahzib
Back to previous
Standard versus transepithelial corneal crosslinking for progressive keratoconus
University Medical Center Utrecht, The Netherlands
In this randomised clinical trial, 80 patients will be treated by either standard or TE CXL. We will demonstrate the 6-month follow-up of 28 treated eyes (10 standard and 18 TE). Visual and refractive data, pachymetry and keratometry were analysed.
No further progression of keratoconus was noted in both groups. Maximal keratometry was stable in the TE group, and decreased in the standard group. Corrected visual acuity (CDVA) improved significantly in the TE group (0.28 to 0.15 logMAR). In the standard CXL group, 2 eyes developed minor complications due to healing problems (infiltrate and herpes).
Our preliminary results show that TE CXL could be effective and safe, without epithelial healing problems.